Med Tech-related technology assessments and clinical guidelines from NICE in November 2021

09

Dec 2021

In November 2021, NICE published two Interventional Procedures Guidance (IPG):

  • Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure;
  • Coronary sinus narrowing device implantation for refractory angina.

IPG is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

NICE made the following conclusions:

Medical Technologies Guidance (MTG) evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that deliver treatment, like those implanted during surgical procedures, give greater independence to patients, or detect or monitor medical conditions.

In November 2021, NICE issued one new MTGs on Synergo for non-muscle-invasive bladder cancer. Synergo treats non-muscle-invasive bladder cancer using a radiofrequency-induced thermo-chemotherapeutic effect (RITE). NICE concluded that Synergo shows promise for high-risk non-muscle-invasive bladder cancer that has not responded to or has recurred after Bacillus Calmette-Guerin (BCG) treatment or when people cannot or do not want to have BCG treatment. However, there is not enough good-quality evidence to support the case for routine adoption. Synergo should only be used with special arrangements as outlined by NICE interventional procedures guidance on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628). Further research is recommended.

The Diagnostic Guidance (DG) program focuses on evaluating innovative medical diagnostic technologies to ensure that the NHS can adopt clinically and cost-effective technologies rapidly and consistently.

In November 2021, NICE published one new DG on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhea. NICE concluded that there is not enough evidence to recommend routine use of SeHCAT for diagnosing bile acid diarrhea in people with 1) chronic diarrhea of unknown cause, suspected or diagnosed diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea; 2) Crohn's disease without ileal resection who have chronic diarrhea. Centers already using SeHCAT for diagnosing bile acid diarrhea may continue to do so but must collect further data or do further research. Further data collection and research are being recommended.

The MedTech Innovation Briefings (MIBs) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations. The four new MIBs published in November 2021 are:

Three new clinical guidelines were published in November 2021:

Six clinical guidelines were updated in November 2021:

See the full details for guidance here. and for MIBs here

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

20

May 2022

In April 2022, NHS England and NHS Improvement (NHSEI) announced that the timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23 are currently under review. Previously, NHSEI planned to publish and implement the 2022/23 Test Directory by April 2022. While the timelines are not confirmed, applications can still be submitted.

Read more

17

May 2022

On April 21, 2022, NHS England and NHS Improvement updated the 2021/22 National Genomic Test Directory (version 3), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Forty-two new codes (test-indication combinations) were introduced in the cancer field, and fourteen for rare and inherited diseases.

Read more

16

May 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in April 2022. Thirty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, neurovascular, and neuromodulation and other devices, as well as medical aids.

Read more

13

May 2022

In April 2022, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 0183 and 0080 with changes to be implemented no later than June 14, 2022. Eleven new procedure codes and nine new diagnostic codes were introduced.

Read more

12

May 2022

MoveUP is the first digital health app that has reached the level 3 level on the Mhealth validation pyramid. This means that the app is now reimbursed in Belgium.

Read more